invuity investor presentation - shareholders meeting includes q1 2016 results - may 2016

8/16/2019 Invuity Investor Presentation - Shareholders Meeting Includes Q1 2016 Results - May 2016

1/38

1


2/38

2

2

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. Thesestatements relate to future events or the Company’s future financial performance and involve known and unknown risks,uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of theCompany or its industry to be materially different from those expressed or implied by any forward-looking statements. Insome cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,”“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparableterminology. All statements other than statements of historical fact could be deemed forward-looking, including anyexpectations regarding investment returns; any projections of financial information; any statements about historicalresults that may suggest trends for our business; any statements of the plans, strategies, and objectives of managementfor future operations; any statements of expectation or belief regarding future events, potential markets or market size,or technology developments; and any statements of assumptions underlying any of the items mentioned. The Companyhas based these forward-looking statements on its current expectations, assumptions, estimates and projections. Whilethe Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond theCompany’s control. These and other important factors may cause actual results, performance or achievements to differmaterially from those expressed or implied by these forward-looking statements. These statements may involve risksand uncertainties that could cause actual results to differ materially from the expected results. Such risks include butare not limited to the risk factors set forth in the Company’s most recent Form 10-K, Form 10-Q and other filings with the

Securities and Exchange Commission (SEC). Investors are urged to review the Company’s SEC filings. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, the Companyassumes no obligation and does not intend to update these forward-looking statements or to conform these statementsto actual results or to changes in the Company's expectations.

Forward-Looking Statements


3/38

3

3

NASDAQ: IVTY

Philip Sawyer, Chief Executive Officer Jim Mackaness, Chief Financial Officer


4/38

4

4


5/38

5

5

of all surgical procedures are openminimally invasive and minimal access*

* Based on company estimate for the U.S.5


6/38

6


7/38

7

Proprietary Intelligent Photonics™ Technology

~ 2.0B US Market

162,000 Procedures

>61% YoY Revenue Growth 2015 vs. 2014

Platform Technology--9 Product Families

Company Snapshot*

~80% of Revenue from Single–Use Devices

~

* As of March 31, 2016


8/38

88


9/38

99

overheadlights

fiberoptics

headlights

9


10/38

10

POORVISUALIZATION

10


11/38

1111

IntelligentPhotonics ™

Technology03.REFRACTIVEMICROSTRUCTURES

04.THERMALLY COOLILLUMINATION

01.SOLID COREOPTICAL POLYMER

02.TOTAL INTERNALREFLECTION AND LIGHTMIXING


12/38

1212

01. SOLID COREOPTICAL POLYMER

Efficient transmission oflight

Less heatbuildup

Efficient coupling

01.SOLID COREOPTICAL POLYMER


13/38

1313

02. TOTAL INTERNALREFLECTION

AND LIGHT MIXING

Efficient transmission oflight prior to extraction

02.TOTAL INTERNALREFLECTION AND LIGHTMIXING

Light mixing reducesglare and bright spots


14/38

1414

03. REFRACTIVEMICROSTRUCTURES

Off-axis lightextraction

Broad, uniform,volumetricillumination

Reducedshadows andglare

03.REFRACTIVEMICROSTRUCTURES


15/38

15

TEMPERATURE (C˚)

50.3 °CmaximumAt 44˚C and above a

burn can occur

15

IntelligentPhotonics™Technology

TraditionalFiber Optic

33.2 °Cmaximum

* Per co. bench testing

*


16/38

16

LIGHT PROJECTION

IntelligentPhotonics™Technology

TraditionalFiber Optic

16* Per co. bench testing

*


17/38

17 1717 RetractorDrop-in Handheld

Saber

Yankauer™

Saber

Frazier™

XT

System™ Eikon™

Eika™ Eivector™ Breiten™ Eipex™ Eiberg™


18/38

18

/ /


19/38

1919


20/38

20

*Company estimate

Initial US Beachhead Specialties TAM $1.1B

2B US Total Available Market


21/38

21

TRAUMA/TUMOR(Ortho)

LUMBAR(Spine)

SHOULDER(Ortho)

BREASTONCOLOGY

HIP (Ortho)

CERVICAL (Spine)

BREASTRECONSTRUCTION

Other Specialties

21

Specialties


22/38

22

Breast Oncology and Reconstruction Opportunity

Key Procedure Targets

• Nipple Sparing Mastectomy

• Skin Sparing Mastectomy• Breast Reconstruction• Lumpectomy


23/38

23

Superior Visualization During...Nipple Sparing Mastectomy


24/38

24

92

…report Eikon improves patient safety

100

9292 …report Eikon reduces heat and thermalhazards in operating room

…report Eikon improves surgical efficiency

in performing NSMs

…report that Eikon reduces procedure

time for NSMs. Approximately 36 minutesOR time saved

Breast Surgeon Survey Results*

* Survey of 12 breast oncology surgeon thought leaders24


25/38

252525

RETROSPECTIVE CHART REVIEW OF NIPPLE SPARING MASTECTOMIES WITH AND WITHOUT AENABLING INTRACAVITY ILLUMINATION AND VISUALIZATION SYSTEM

Authors : Beth Baughman DuPree MD, FACS, ABIHM, William Scarlett DO, FACS, FACOS, FAACS,Anna Smaron, Marie Cassese, Darren Eskow, and Jeff Gross

ffili tions : Adjunct Assistant Professor of Surgery University of Pennsylvania, Philadelphia PA,Chairman Department of Surgery Holy Redeemer Hospital, Medical Director Integrative MedicineHoly Redeemer Health System, Meadowbrook, PA Associate Professor of Plastics Surgery,PCOM, Philadelphia PA, Medical Director of Bucks County Aesthetic Center, Bensalem, PA

Procedure: Unilateral and Bilateral Nipple Sparing MastectomyResults:*Average of 31 min. reduction in anesthesia time in bilateral NSM20% increase in procedures among patients with C and D cup size100% decrease in compromised flaps in combined unilateral/bilateral surgeries**70% decrease in epidermolysis in combined unilateral/bilateral surgeries**_____________________________________________________________________________

Total potential savings of 580 to 2000 per procedure using Invuity devices***

* Results reflect changes after surgeon adoption of Invuity’s Eikon illuminated retractor system** Due to introduction of Invuity's Eikon Illuminated retractor system and potentially the advanced electrosurgical device*** Study and economic analysis performed by leading outside healthcare consulting firm


26/38

262626

• Surgeon Certification and Training Program onOncoplastic Techniques

• Women’s Health Focus—Breast, Thyroid,Gynecology

• Center of Excellence Certification and Designation

Online

• Hidden Scar™ Centers ofExcellence Finder atBreastCancerSurgery.com

• Hidden Scar™ Certified SurgeonFinder atBreastCancerSurgery.com

• My Hidden Scar Microsite atMyHiddenScar.com

• Social media (Facebook, Twitter,Pinterest)

External Marketing

• Radio Spots• Print Ads• Billboard Ads• Media Relations/PR

• Newsletter Templates• Website templates• Patient Education Presentation• Referral Letters

Internal Marketing

• On-hold message• Waiting Room Patient Education

Video• Lobby/Waiting Room Displays and

Wall Posters• Patient Education Brochures

mailto:www.breastcancersurgery.commailto:www.breastcancersurgery.commailto:www.myhiddenscar.commailto:www.myhiddenscar.commailto:www.breastcancersurgery.commailto:www.breastcancersurgery.com


27/38

272727


28/38

Orthopedics

Saber Frazier™ Saber Yankauer™

Eiberg™

Eipex™Eivector™


29/38

29


MIS Anterior Hip Arthroplasty Shoulder Arthroplasty

Foot and Ankle Hip Revisions Trauma

Orthopedics Opportunity


30/38

303030

Anterior Hip Arthroplasty—Visualization of the Femoral Canal


31/38

313131

Spine Opportunity


Posterior lumbar decompression Posterior lumbar fusion Anterior lumbar fusion

Anterior and posterior cervicaldecompression

Anterior cervical fusion


32/38

323232

Saber Frazier™ in Posterior Lumbar Fusion

Superior visualization. Ability to achieve rapid hemostasis.


33/38

33

Expand “deeper” to new surgicalprocedures and specialties—top/down strategy

~162,000 procedures

performed to date vs. ~92,000as of Q1 2015

Expanding US sales organization

Customer account growth—545accounts Q1 2016 vs. 410 Q12015

CommercializationStrategy


34/38

34

Financial Overview


35/38

35

Topline Growth Year Over Year


36/38


37/38

37

Experienced Management Team

Large Under-Penetrated Market

Significant Clinical & Product Advantageswith Strong IP

Favorable Economics

Investment Summary


38/38

38

invuity investor presentation - shareholders meeting includes q1 2016 results - may 2016

Documents